Literature DB >> 21757725

L-Ala-γ-D-Glu-meso-diaminopimelic acid (DAP) interacts directly with leucine-rich region domain of nucleotide-binding oligomerization domain 1, increasing phosphorylation activity of receptor-interacting serine/threonine-protein kinase 2 and its interaction with nucleotide-binding oligomerization domain 1.

Hamed Laroui1, Yutao Yan, Yoshie Narui, Sarah A Ingersoll, Saravanan Ayyadurai, Moiz A Charania, Feimeng Zhou, Binghe Wang, Khalid Salaita, Shanthi V Sitaraman, Didier Merlin.   

Abstract

The oligopeptide transporter PepT1 expressed in inflamed colonic epithelial cells transports small bacterial peptides, such as muramyl dipeptide (MDP) and l-Ala-γ-D-Glu-meso-diaminopimelic acid (Tri-DAP) into cells. The innate immune system uses various proteins to sense pathogen-associated molecular patterns. Nucleotide-binding oligomerization domain (NOD)-like receptors of which there are more than 20 related family members are present in the cytosol and recognize intracellular ligands. NOD proteins mediate NF-κB activation via receptor-interacting serine/threonine-protein kinase 2 (RICK or RIPK). The specific ligands for some NOD-like receptors have been identified. NOD type 1 (NOD1) is activated by peptides that contain a diaminophilic acid, such as the PepT1 substrate Tri-DAP. In other words, PepT1 transport activity plays an important role in controlling intracellular loading of ligands for NOD1 in turn determining the activation level of downstream inflammatory pathways. However, no direct interaction between Tri-DAP and NOD1 has been identified. In the present work, surface plasmon resonance and atomic force microscopy experiments showed direct binding between NOD1 and Tri-DAP with a K(d) value of 34.5 μM. In contrast, no significant binding was evident between muramyl dipeptide and NOD1. Furthermore, leucine-rich region (LRR)-truncated NOD1 did not interact with Tri-DAP, indicating that Tri-DAP interacts with the LRR domain of NOD1. Next, we examined binding between RICK and NOD1 proteins and found that such binding was significant with a K(d) value of 4.13 μM. However, NOD1/RICK binding was of higher affinity (K(d) of 3.26 μM) when NOD1 was prebound to Tri-DAP. Furthermore, RICK phosphorylation activity was increased when NOD was prebound to Tri-DAP. In conclusion, we have shown that Tri-DAP interacts directly with the LRR domain of NOD1 and consequently increases RICK/NOD1 association and RICK phosphorylation activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21757725      PMCID: PMC3162459          DOI: 10.1074/jbc.M111.257501

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Normal responses to specific NOD1-activating peptidoglycan agonists in the presence of the NOD2 frameshift and other mutations in Crohn's disease.

Authors:  David A van Heel; Karen A Hunt; Subrata Ghosh; Mireille Hervé; Raymond J Playford
Journal:  Eur J Immunol       Date:  2006-06       Impact factor: 5.532

Review 2.  Recognition of bacterial peptidoglycan by the innate immune system.

Authors:  R Dziarski
Journal:  Cell Mol Life Sci       Date:  2003-09       Impact factor: 9.261

3.  Topography and recognition imaging of protein-patterned surfaces generated by AFM nanolithography.

Authors:  Rong Zhu; Andreas Ebner; Markus Kastner; Johannes Preiner; Stefan Howorka; Peter Hinterdorfer
Journal:  Chemphyschem       Date:  2009-07-13       Impact factor: 3.102

Review 4.  Innate immune sensing of microbes by Nod proteins.

Authors:  Thomas A Kufer; Diana J Banks; Dana J Philpott
Journal:  Ann N Y Acad Sci       Date:  2006-08       Impact factor: 5.691

5.  Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease.

Authors:  D A van Heel; S Ghosh; K A Hunt; C G Mathew; A Forbes; D P Jewell; R J Playford
Journal:  Gut       Date:  2005-05-31       Impact factor: 23.059

6.  Determination of rate and equilibrium binding constants for macromolecular interactions by surface plasmon resonance.

Authors:  D J O'Shannessy; M Brigham-Burke; K K Soneson; P Hensley; I Brooks
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

7.  Sub-attomole oligonucleotide and p53 cDNA determinations via a high-resolution surface plasmon resonance combined with oligonucleotide-capped gold nanoparticle signal amplification.

Authors:  Xin Yao; Xin Li; Freddy Toledo; Cecilia Zurita-Lopez; Margarita Gutova; Jamil Momand; Feimeng Zhou
Journal:  Anal Biochem       Date:  2006-05-06       Impact factor: 3.365

8.  Synergistic enhancement of Toll-like receptor responses by NOD1 activation.

Authors:  David A van Heel; Subrata Ghosh; Matt Butler; Karen Hunt; Brian Michael J Foxwell; Dominique Mengin-Lecreulx; Raymond J Playford
Journal:  Eur J Immunol       Date:  2005-08       Impact factor: 5.532

9.  Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island.

Authors:  Jérôme Viala; Catherine Chaput; Ivo G Boneca; Ana Cardona; Stephen E Girardin; Anthony P Moran; Rafika Athman; Sylvie Mémet; Michel R Huerre; Anthony J Coyle; Peter S DiStefano; Philippe J Sansonetti; Agnès Labigne; John Bertin; Dana J Philpott; Richard L Ferrero
Journal:  Nat Immunol       Date:  2004-10-17       Impact factor: 25.606

10.  NOD1-Mediated Mucosal Host Defense against Helicobacter pylori.

Authors:  Tomohiro Watanabe; Naoki Asano; Atsushi Kitani; Ivan J Fuss; Tsutomu Chiba; Warren Strober
Journal:  Int J Inflam       Date:  2010-07-15
View more
  44 in total

1.  Neisseria gonorrhoeae PBP3 and PBP4 Facilitate NOD1 Agonist Peptidoglycan Fragment Release and Survival in Stationary Phase.

Authors:  Ryan E Schaub; Krizia M Perez-Medina; Kathleen T Hackett; Daniel L Garcia; Joseph P Dillard
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

Review 2.  Messenger functions of the bacterial cell wall-derived muropeptides.

Authors:  Marc A Boudreau; Jed F Fisher; Shahriar Mobashery
Journal:  Biochemistry       Date:  2012-03-27       Impact factor: 3.162

Review 3.  Emerging significance of NLRs in inflammatory bowel disease.

Authors:  Beckley K Davis; Casandra Philipson; Raquel Hontecillas; Kristin Eden; Josep Bassaganya-Riera; Irving C Allen
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

4.  Expression, purification, and characterization of recombinant NOD1 (NLRC1): A NLR family member.

Authors:  Nadav Askari; Ricardo G Correa; Dayong Zhai; John C Reed
Journal:  J Biotechnol       Date:  2011-10-28       Impact factor: 3.307

Review 5.  NOD proteins: regulators of inflammation in health and disease.

Authors:  Dana J Philpott; Matthew T Sorbara; Susan J Robertson; Kenneth Croitoru; Stephen E Girardin
Journal:  Nat Rev Immunol       Date:  2013-12-13       Impact factor: 53.106

Review 6.  International Union of Basic and Clinical Pharmacology. XCVI. Pattern recognition receptors in health and disease.

Authors:  Clare E Bryant; Selinda Orr; Brian Ferguson; Martyn F Symmons; Joseph P Boyle; Tom P Monie
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

7.  Trace levels of peptidoglycan in serum underlie the NOD-dependent cytokine response to endoplasmic reticulum stress.

Authors:  Raphael Molinaro; Tapas Mukherjee; Robert Flick; Dana J Philpott; Stephen E Girardin
Journal:  J Biol Chem       Date:  2019-04-17       Impact factor: 5.157

8.  Peptidoglycan Metabolite Photoaffinity Reporters Reveal Direct Binding to Intracellular Pattern Recognition Receptors and Arf GTPases.

Authors:  Yen-Chih Wang; Nathan P Westcott; Matthew E Griffin; Howard C Hang
Journal:  ACS Chem Biol       Date:  2019-02-20       Impact factor: 5.100

Review 9.  Peptidoglycan recognition by the innate immune system.

Authors:  Andrea J Wolf; David M Underhill
Journal:  Nat Rev Immunol       Date:  2018-01-02       Impact factor: 53.106

10.  Fab'-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis.

Authors:  Hamed Laroui; Emilie Viennois; Bo Xiao; Brandon S B Canup; Duke Geem; Timothy L Denning; Didier Merlin
Journal:  J Control Release       Date:  2014-05-05       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.